Invasive aspergillosis: a severe infection in juvenile systemic lupus erythematosus patients


Autoria(s): Silva, M. F.; Ribeiro, A. S.; Fiorot, F. J.; Aikawa, N. E.; Lotito, A. P.; Campos, L. M.; Mauad, T.; Silva, C. A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

29/10/2013

29/10/2013

2012

Resumo

Infections are an important cause of morbidity and mortality in juvenile systemic lupus erythematosus (JSLE). Among them, invasive aspergillosis (IA), which is usually related to immunosuppressed patients, has been rarely reported in JSLE. From 1983 to 2011, 5604 patients were followed at our institution and 283 (5%) met the American College of Rheumatology (ACR) classification criteria for SLE. Six (2.1%) of our JSLE patients had IA. One of them was previously reported and five will be described herein. Four of them were female. The median age at JSLE diagnosis was 12 years (8-16) and the median interval between diagnosis of JSLE and IA was 6 months (1-38). All had pulmonary involvement and three of them had systemic involvement. The median Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) was 19 (7-22). Diagnosis of IA was performed by isolation of Aspergillus spp., two in bronchoalveolar lavage culture and by way of autopsy in the others. All of them were treated with corticosteroids and/or immunosuppressive drugs at IA diagnosis (azathioprine and/or intravenous cyclophosphamide). They all required treatment in the pediatric intensive care unit with mechanical ventilation and antifungal therapy (fluconazole, amphotericin B, itraconazole and/or voriconazole); nonetheless, none of them survived. In conclusion, this was the first report that evaluated the prevalence of IA in a large population of JSLE patients from a tertiary pediatric hospital, and clearly showed the severity of the outcome, especially in patients with active disease and treated with immunosuppressive agents. This study reinforces the importance of early diagnosis and treatment with certain antifungals, especially in critically ill patients. Lupus (2012) 21, 1011-1016.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP [08/58238-4]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPQ [302724/2011-7]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Federico Foundation

Federico Foundation

Identificador

LUPUS, LONDON, v. 21, n. 9, supl. 1, Part 1, pp. 1011-1016, AUG, 2012

0961-2033

http://www.producao.usp.br/handle/BDPI/36271

10.1177/0961203312442752

http://dx.doi.org/10.1177/0961203312442752

Idioma(s)

eng

Publicador

SAGE PUBLICATIONS LTD

LONDON

Relação

LUPUS

Direitos

closedAccess

Copyright SAGE PUBLICATIONS LTD

Palavras-Chave #INVASIVE ASPERGILLOSIS #INFECTION #JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS #FUNGAL-INFECTIONS #PULMONARY INVOLVEMENT #RISK-FACTORS #DISEASE #INDEX #RHEUMATOLOGY
Tipo

article

original article

publishedVersion